will compounded glp 1 go away FDA is moving to restrict mass-marketed GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified Compounded GLP-1 injection - Personalized
Description
Conclusions GLP-1 RAs have emerged as novel agents in managing CVD, extending their utility beyond glycemic control in T2DM
states and are not available in Louisiana or outside the United States
Additionally, the focus should be on marketing products as nutritional support or companion products rather than as an alternative to GLP-1 drugs
Earlier risk estimate: ~1 in 10,000 patients New finding: ~1 in 2,500 patients No known treatment for NAION Other reported conditions include optic nerve inflammation, maculopathy, and worsening diabetic retinopathy
Furthermore, anecdotal and emerging research suggest potential benefits in conditions such as non-alcoholic fatty liver disease
